FDA Approves ImmunoGen/Roche Breast Cancer Drug

The Food and Drug Administration has approved a new type of breast cancer drug developed by ImmunoGen (NASDAQ: IMGN  ) and Roche (NASDAQOTH: RHHBY  ) , and will be marketed by the latter. The medication, known by the brand name Kadcyla, is used to treat HER 2-positive metastatic breast cancer. It is a combination of Herceptin, an existing Roche drug, with a pair of components developed by ImmunoGen.

HER2 is a protein found on the tumors of roughly 20% to 25% of patients with breast cancer.

The approval will trigger a $10.5 million payment from Roche to ImmunoGen. The latter will also be paid royalties of up to 5% on sales of Kadcyla, which will cost $9,800 per month.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2272999, ~/Articles/ArticleHandler.aspx, 8/1/2014 4:22:25 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement